# Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

> **NCT01022762** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 440 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** repaglinide
- **DRUG:** gliclazide

## Key facts

- **NCT ID:** NCT01022762
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2014-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022762, "Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01022762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*